Linezolid use in medicin therapy against multiresistant bacteria

Abstract

After the appearance and the description of an element with the ability to combat the infectious processes originating from bacteria, not expected with the natural selection of prokaryotic microorganisms. This ability has made the survival begin a race between the interrelationship of species, bacterial and human. With the evolution scientific-technical, the man was able to synthesize antibacterial, however, development mechanisms of gene enabled the emergence of multidrug-resistant bacteria. Some of this frequent on hospital environment and great adaptability to new drugs, with S. aureus and Enterococcus spp, resistant to oxacillin and vancomycin, consider drugs of choice for multidrug-resistant microorganisms. So, a new class was developed superior to vancomycin, oxazolidinone, the linezolid. Thus the present study aimed at understanding the use of linezolid in drug therapy against multiresistant bacteria. To perform this study a literature review of the past 10 years was performed. In 2002, after the liberation of the use of linezolid as treatment for infectious processes against gram-positive bacteria, was commonly used throughout the world. Similarly, the pressure of natural selection to records of the highlight strains resistant to linezolid use. As prospects for control of infections caused by these resistant strains was approved by the FDA in 2014 the use of drugs with an anti-linezolid-resistant strains activity. However we conclude that the addition to natural selection and genetic variation process, human behavior regarding the use of antibiotics, increases the selection of resistant microorganisms, including linezolid.